Table 1.

MSC from BM after osteodifferentiation and licensing by IFN-γ and TNF-α do not induce PBMC proliferation in allogenic conditions.

R : Sa  ratio	MSC-BM	MSC-BM IFN-γ/TNF-α	Os-MSC-BM	Os-MSC-BM IFN-γ/TNF-α
1 : 0.5	4.3 ± 2.1b	1.1 ± 0.3	3.3 ± 0.3	1.7 ± 0.2
1 : 0.25	4.5 ± 1.4	1.0 ± 0.3	3.1 ± 0.1	1.8 ± 0.5
1 : 0.12	5.3 ± 1.9	1.1 ± 0.4	3.2 ± 1.0	2.3 ± 1.2
1 : 0.06	5.4 ± 2.4	1.4 ± 0.5	2.6 ± 1.1	3.9 ± 3.1
1 : 0.03	4.3 ± 1.7	1.4 ± 0.5	2.2 ± 0.2	2.1 ± 1.2

^aPBMC from healthy individuals were used as responder cells towards BM-derived MSCs pretreated with IFN-γ and TNF-α (MSC-BM IFN-γ/TNF-α) or not (MSC-BM) as stimulating cells at various responder : stimulator (R : S) ratios. Similar experiments were performed with BM-derived MSCs committed to osteodifferentiation process and pretreated with IFN-γ and TNF-α (Os-MSC-BM IFN-γ/TNF-α) or not (Os-MSC-BM) as stimulating cells.

^bData are mean ± s.e.m. of alloproliferation percentage obtained with 5 and 3 distinct healthy donors for MSC-BM and Os-MSC-BM experiments, respectively. This percentage is calculated considering PBMC stimulated with LCL* as 100% alloproliferation.